Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?

Sulphonylureas (SU) form an important role in management of people with type 2 diabetes. This safety history of SU was tainted for various reasons, the predominant one being lack of demonstration of cardiovascular safety. Since its introduction, SU's have never been subjected to a formal study...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Mathew, Kalra, Sanjay, Nair, Tiny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Opinion Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474120/
https://www.ncbi.nlm.nih.gov/pubmed/32861392
http://dx.doi.org/10.1016/j.ihj.2020.07.009
Descripción
Sumario:Sulphonylureas (SU) form an important role in management of people with type 2 diabetes. This safety history of SU was tainted for various reasons, the predominant one being lack of demonstration of cardiovascular safety. Since its introduction, SU's have never been subjected to a formal study for its cardiovascular safety. The cardiovascular safety of SUs was derived from small, inadequately powered randomised controlled trials (RCT) and observational studies. CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) trial planned as a cardiovascular outcome trial randomised people with type 2 diabetes and high cardiovascular risk to Linagliptin and Glimepiride. This opinion paper outlines the salient features of this landmark trial and its implications in general cardiology practice.

Ejemplares similares